| Airbnb (NASDAQ:ABNB) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $175.00 price target on the stock, up previously from $140.00. This represents a 9.5% upside from the current price of $159.80. |
| Airbnb (NASDAQ:ABNB) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "sell" rating to a "neutral" rating. They now have a $153.00 price target on the stock, up previously from $110.00. This represents a 4.3% downside from the current price of $159.80. |
| Airbnb (NASDAQ:ABNB) was upgraded by analysts at Gordon Haskett from a "sell" rating to a "hold" rating. They now have a $143.00 price target on the stock. This represents a 10.5% downside from the current price of $159.80. |
| Airbnb (NASDAQ:ABNB) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating.The current price is $159.80. |
| Brookfield Asset Management (NYSE:BAM) (TSE:BAM.A) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating.The current price is $59.26. |
| Bridgeline Digital (NASDAQ:BLIN) was upgraded by analysts at Westpark Capital from a "hold" rating to a "buy" rating. They now have a $4.62 price target on the stock. This represents a 137.5% upside from the current price of $1.95. |
| Brixmor Property Group (NYSE:BRX) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $33.00 price target on the stock, up previously from $28.00. This represents a 16.6% upside from the current price of $28.29. |
| Carrier Global (NYSE:CARR) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $78.00 price target on the stock. This represents a 21.7% upside from the current price of $64.11. |
| CRISPR Therapeutics (NASDAQ:CRSP) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $99.00 price target on the stock, up previously from $60.00. This represents a 88.9% upside from the current price of $52.40. |
| Floor & Decor (NYSE:FND) was upgraded by analysts at Telsey Advisory Group from a "market perform" rating to an "outperform" rating. They now have a $115.00 price target on the stock, up previously from $95.00. This represents a 14.2% upside from the current price of $100.70. |
| Mid-America Apartment Communities (NYSE:MAA) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $182.00 price target on the stock, up previously from $173.00. This represents a 14.6% upside from the current price of $158.86. |
| MGM Resorts International (NYSE:MGM) was upgraded by analysts at Argus from a "hold" rating to a "buy" rating. They now have a $50.00 price target on the stock. This represents a 22.5% upside from the current price of $40.80. |
| Roku (NASDAQ:ROKU) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $129.00 price target on the stock, up previously from $74.00. This represents a 29.3% upside from the current price of $99.79. |
| Roku (NASDAQ:ROKU) was upgraded by analysts at Pivotal Research from a "hold" rating to a "buy" rating. They now have a $125.00 price target on the stock, up previously from $65.00. This represents a 25.3% upside from the current price of $99.79. |
| Upstart (NASDAQ:UPST) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $70.00 price target on the stock, up previously from $12.00. This represents a 15.0% downside from the current price of $82.34. |
| Welltower (NYSE:WELL) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $167.00 price target on the stock, up previously from $145.00. This represents a 11.4% upside from the current price of $149.91. |
| Warner Music Group (NASDAQ:WMG) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $42.00 price target on the stock, up previously from $34.00. This represents a 16.1% upside from the current price of $36.17. |
| West Pharmaceutical Services (NYSE:WST) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating. They now have a $250.00 price target on the stock. This represents a 16.6% upside from the current price of $214.34. |
Ratings changes for Roku, CRISPR Therapeutics, CRISPR Therapeutics, T2 Biosystems, Remark, Abeona Therapeutics, Matrix Service and more...Upgrade to MarketBeat All Access to get early delivery, personalized stock alerts, portfolio monitoring tools, and more. Start Your Free Trial. 
